Fig. 1: AAV1.NT-3 treatment improves clinical scores and functional tests in the EAE mice. | Gene Therapy

Fig. 1: AAV1.NT-3 treatment improves clinical scores and functional tests in the EAE mice.

From: AAV1.NT3 gene therapy mitigates the severity of autoimmune encephalomyelitis in the mouse model for multiple sclerosis

Fig. 1

Clinical scores in females (A) and males (B) from untreated (UT) and treated (NT-3) cohorts are shown. Higher clinical scores indicate more severe symptoms in the mice. Red line indicates the timepoint for AAV1.NT3 injection. Clinical scores between days 0–21 were not statistically different (ns) between cohorts. Grip strength (C, D) and rotarod (E, F) analyses from females and males respectively, with or without AAV1.NT-3 treatment. Data represents Mean ± SEM (Female cohort: n = 7 for untreated, and n = 9 for NT-3 treated; male cohort: n = 8 for untreated, and n = 9 for NT-3 treated cohorts). Two-way ANOVA, *p < 0.05.

Back to article page